Shoulder Innovations filings document a Delaware medical technology issuer focused on shoulder arthroplasty implants and related surgical-care technologies. Form 8-K reports cover operating results, Regulation FD disclosures, product-launch announcements, FDA-cleared indications, strategic partnership announcements, and material agreements tied to corporate facilities.
Governance filings include the definitive proxy statement for the annual meeting, director elections, board committee matters, non-employee director compensation, and stockholder voting procedures. Current reports also record director appointments, resignations, independence determinations, indemnification arrangements and other corporate-governance events.
Shoulder Innovations, Inc. CEO & Executive Chairman Robert Joseph Ball exercised stock options for 66,757 common shares on October 30, 2026, at an exercise price of $2.4804 per share. The reported position following the transaction was 242,999 stock options. On the same date, 29,639 common shares were delivered or withheld for payment of exercise price or tax liability; the reported price for those shares was $20.44 per share. The transactions were not reported as made under a Rule 10b5-1 plan.
Shoulder Innovations, Inc. initiated a limited user release of InSet Go, its next-generation glenoid implant for anatomic shoulder arthroplasty, after the first surgical case was performed by Robert Gillespie, MD, of University Hospitals Cleveland Medical Center. The company says the design retains the original InSet approach of imprinting the implant within a circumferential rim of supportive bone.
The company says InSet Go includes additional intellectual-property elements related to the articular surface and InSet PLUS augmented configurations important for correcting bone loss. Shoulder Innovations said it looks forward to a full commercial introduction over the coming quarters.
Shoulder Innovations, Inc. (SI) reported that director and ten-percent owner Casey M. Tansey acquired 733 restricted stock units on October 5, 2026, with a reported per-share value of $19.60. The RSUs were granted in lieu of cash retainer fees and were fully vested as of the grant date; Tansey elected to defer receipt of the common shares issuable upon settlement until departure from the board. The direct common-stock position reported after the award was 53,445 shares. Indirect holdings listed through U.S. Venture Partners XII, L.P., U.S. Venture Partners XII-A, L.P., and U.S. Venture Partners Select Fund I, L.P. were 1,686,403, 85,586, and 921,130 shares, respectively. Tansey may be deemed to share voting and dispositive power over those fund holdings and disclaims beneficial ownership except to the extent of any pecuniary interest.
Shoulder Innovations, Inc. director Kevin K. Sidow received an award of 892 restricted stock units (RSUs) on October 5, 2026, reported at $19.60 per share. The RSUs were fully vested as of the grant date and were received in lieu of cash retainer fees. Each RSU represents a contingent right to receive one common share; Sidow voluntarily deferred receipt of the shares issuable upon settlement until his departure from the Board of Directors. The reported direct position following the transaction was 25,948 shares.
Andrew Hykes, a director of Shoulder Innovations, Inc. (SI), acquired 669 restricted stock units on October 5, 2026, in lieu of cash retainer fees. The units were fully vested as of the grant date; each represents a contingent right to one share of common stock and has no expiration date. Hykes elected to defer receipt of the shares issuable upon settlement until his departure from the Board of Directors. His reported direct position after the award was 7,438 shares.
Shoulder Innovations, Inc. (SI) director Paul Buckman acquired an award of 1,275 restricted stock units on October 5, 2026, in lieu of cash retainer fees. The RSUs were fully vested on the grant date, and each represents a contingent right to one common share. Buckman elected to defer receipt of shares issuable upon settlement until his departure from the Board; his reported direct holdings following the award were 65,025 shares.
SHOULDER INNOVATIONS, INC. (SI) reports that CEO & Executive Chairman Robert Joseph Ball exercised stock options to acquire 89,233 shares of Common Stock on September 14, 2026 at an exercise price of $2.0988 per share, from a fully vested, currently exercisable option expiring December 16, 2030. On the same date, he sold 10,175 shares of Common Stock at a weighted average price of $18.4478 per share, with sale prices ranging from $18.22 to $18.63; the disclosure states these shares were sold solely to cover the exercise price. The filing notes that his Common Stock holdings include 1,748 shares acquired on June 30, 2026 under the 2025 Employee Stock Purchase Plan, and no Rule 10b5-1 trading plan is reported.
SHOULDER INNOVATIONS, INC. (SI) received a Rule 144 notice from stockholder Robert Joseph Ball covering a proposed sale of up to 10,175 shares of common stock through Morgan Stanley Smith Barney LLC on or after September 14, 2026. The shares have an aggregate market value of $187,706.37 and are part of an outstanding total of 20,819,000 common shares. The shares to be sold were acquired for cash in private acquisitions from the issuer or an affiliate on March 6, 2025 (4,386 shares), June 20, 2025 (3,289 shares), and July 9, 2025 (2,500 shares).
SHOULDER INNOVATIONS, INC. (SI) insider Gilde Healthcare Holding B.V., a ten percent owner, reported an indirect open-market sale of 1,196 shares of common stock on 2026-08-26 at $22.60 per share. After this transaction, the reporting group’s indirect holdings total 2,185,914 shares, held through affiliated Gilde entities, with certain partners disclaiming full beneficial ownership.
SHOULDER INNOVATIONS, INC. (SI) reported insider activity by major shareholder Gilde Healthcare Holding B.V., related to shares held through Coöperatieve Gilde Healthcare V U.A. Over August 20–24, 2026, Gilde reported open-market sales totaling 25,097 shares of common stock at weighted average prices around $22.60–$22.78 per share. Voting and dispositive power over the sold shares resides with Gilde Healthcare V Management B.V., and certain individuals, including Geoff Pardo, disclaim beneficial ownership except to the extent of any pecuniary interest.